

## Regulatory Announcement

RNS Number : 53051  
Akers Biosciences, Inc.  
20 November 2008

Embargoed: 0700hrs, 20 November 2008

**Akers Biosciences Inc.**  
("ABI" or the "Company")

### **ABI Signs Multi Product Over-the-Counter Distribution Agreement**

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has signed an agreement with a large U.S. distributor specialising in over-the-counter diagnostic products. The distributor, who cannot be named for commercial reasons, will market several of the Company's products to the U.S. retail market, including Tri-Cholesterol, the only disposable, rapid test in the world to read HDL, LDL and Total cholesterol levels.

Marketing of ABI's products under the agreement will begin immediately to drug, food and convenience stores and mass retailers. Clients include such retailers as Kmart, Wal-Mart, CVS, Walgreens, 7-Eleven, Safeway, Costco and Target.

Currently ABI has limited representation in the U.S. retail markets for over-the-counter sales but this agreement will transform the scale of personnel marketing ABI's products and the regions in which the Company is able to penetrate.

**Thomas Nicolette, President and Chief Executive Officer of ABI said,**

"This agreement represents a significant step in our strategy to penetrate a large segment of the U.S. retail healthcare market to complement our aggressive activities in the hospital and clinical laboratory arenas. There is a clear need for many of our products for use directly by consumers and we are pleased to partner with distributors who have the networks and ability to take our tests to them."

#### **Enquiries:**

Thomas A. Nicolette  
President and CEO  
Tel. +1 856 848 8698

Ben Simons  
M: Communications  
Tel. +44 (0)20 7153 1540

Alasdair Younie  
Arbuthnot Securities Limited  
Tel. +44 (0)20 7012 2000

## **About Akers Biosciences**

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products [distributors](#) to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at [www.akersbiosciences.com](http://www.akersbiosciences.com).

This information is provided by RNS  
The company news service from the London Stock Exchange

END